A N Houghton

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi Immunity against cancer: lessons learned from melanoma
    A N Houghton
    Memorial Sloan Kettering Cancer Center and Weill Medical School of Cornell University, 1275 York Avenue, New York, NY 10021, USA
    Curr Opin Immunol 13:134-40. 2001
  2. ncbi Antigens recognized by autologous antibodies of patients with soft tissue sarcoma
    Neil H Segal
    Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Immun 5:4. 2005
  3. ncbi Focus on melanoma
    Alan N Houghton
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Cell 2:275-8. 2002
  4. ncbi Identification of cancer-testis genes expressed by melanoma and soft tissue sarcoma using bioinformatics
    Neil H Segal
    Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Immun 5:2. 2005
  5. pmc Immune recognition of self in immunity against cancer
    Alan N Houghton
    The Swim Across America Laboratory of Tumor Immunology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Clin Invest 114:468-71. 2004
  6. ncbi The role of the immune system in early epithelial carcinogenesis: B-ware the double-edged sword
    Alan N Houghton
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Cell 7:403-5. 2005
  7. ncbi LIGHTing the way for tumor immunity
    Alan N Houghton
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Nat Immunol 5:123-4. 2004
  8. ncbi Tumor endothelial marker 8 enhances tumor immunity in conjunction with immunization against differentiation Ag
    P Felicetti
    Swim Across America Laboratory of Tumor Immunology, Memorial Sloan Kettering Cancer Center, New York, USA
    Cytotherapy 9:23-34. 2007
  9. ncbi Alternative roles for interferon-gamma in the immune response to DNA vaccines encoding related melanosomal antigens
    J D Wolchok
    The Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Immun 1:9. 2001
  10. ncbi Paucity of functional T-cell memory to melanoma antigens in healthy donors and melanoma patients
    M V Dhodapkar
    Laboratory of Cellular Physiology and Immunology, The Rockefeller University, New York, New York 10021, USA
    Clin Cancer Res 6:4831-8. 2000

Research Grants

  1. IMMUNIZATION AGAINST MELANOMA DIFFERENTIATION ANTIGENS
    Jedd D Wolchok; Fiscal Year: 2010
  2. IMMUNIZATION AGAINST MELANOMA DIFFERENTIATION ANTIGENS
    Alan Houghton; Fiscal Year: 2009
  3. Targeted antigen receptor treatment of cancer
    Alan Houghton; Fiscal Year: 2007
  4. IMMUNIZATION AGAINST MELANOMA DIFFERENTIATION ANTIGENS
    Alan Houghton; Fiscal Year: 2004
  5. ACTIVE IMMUNOTHERAPY OF MELANOMA
    Alan Houghton; Fiscal Year: 1993
  6. IMMUNIZATION AGAINST MELANOMA DIFFERENTIATION ANTIGENS
    ALAN N contact HOUGHTON; Fiscal Year: 2011

Detail Information

Publications70

  1. ncbi Immunity against cancer: lessons learned from melanoma
    A N Houghton
    Memorial Sloan Kettering Cancer Center and Weill Medical School of Cornell University, 1275 York Avenue, New York, NY 10021, USA
    Curr Opin Immunol 13:134-40. 2001
    ..The view of what the immune system can see is extending to mutations and parts of the genome that are normally invisible...
  2. ncbi Antigens recognized by autologous antibodies of patients with soft tissue sarcoma
    Neil H Segal
    Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Immun 5:4. 2005
    ..Further studies of these selected novel STS antigens are warranted to identify and characterize potential antigen targets expressed by STS...
  3. ncbi Focus on melanoma
    Alan N Houghton
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Cell 2:275-8. 2002
  4. ncbi Identification of cancer-testis genes expressed by melanoma and soft tissue sarcoma using bioinformatics
    Neil H Segal
    Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Immun 5:2. 2005
    ....
  5. pmc Immune recognition of self in immunity against cancer
    Alan N Houghton
    The Swim Across America Laboratory of Tumor Immunology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Clin Invest 114:468-71. 2004
  6. ncbi The role of the immune system in early epithelial carcinogenesis: B-ware the double-edged sword
    Alan N Houghton
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Cell 7:403-5. 2005
    ..These are surprising observations, linking antibodies of the adaptive immune system to innate immune responses that drive epithelial carcinogenesis...
  7. ncbi LIGHTing the way for tumor immunity
    Alan N Houghton
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Nat Immunol 5:123-4. 2004
  8. ncbi Tumor endothelial marker 8 enhances tumor immunity in conjunction with immunization against differentiation Ag
    P Felicetti
    Swim Across America Laboratory of Tumor Immunology, Memorial Sloan Kettering Cancer Center, New York, USA
    Cytotherapy 9:23-34. 2007
    ..Tumor endothelial marker 8 (TEM8) is expressed in the neovasculature of human tumors, and in the mouse melanoma B16, but its expression is limited in normal adult tissues. We describe a DNA vaccine combining xenogeneic tumor Ag and TEM8...
  9. ncbi Alternative roles for interferon-gamma in the immune response to DNA vaccines encoding related melanosomal antigens
    J D Wolchok
    The Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Immun 1:9. 2001
    ..These results show that immunity to TRP-2 following DNA immunization uses an IFN-gamma-dependent Th1 pathway, but immunity to gp75/TRP-1 is down-regulated by IFN-gamma...
  10. ncbi Paucity of functional T-cell memory to melanoma antigens in healthy donors and melanoma patients
    M V Dhodapkar
    Laboratory of Cellular Physiology and Immunology, The Rockefeller University, New York, New York 10021, USA
    Clin Cancer Res 6:4831-8. 2000
    ....
  11. ncbi Evaluation of CD8(+) T-cell frequencies by the Elispot assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide
    J J Lewis
    Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Int J Cancer 87:391-8. 2000
    ..1/2,000 in the second patient. These results demonstrate that modest expansion of peptide-specific CD8(+) T cells can be generated in vivo by immunization with peptide plus QS-21 in at least a subset of patients with melanoma...
  12. pmc Cell surface antigens of human melanocytes and melanoma. Expression of adenosine deaminase binding protein is extinguished with melanocyte transformation
    A N Houghton
    Memorial Sloan Kettering Cancer Center, New York 10021
    J Exp Med 167:197-212. 1988
    ..These studies demonstrate that ADAbp expression is lost with malignant transformation of melanocytes, presumably at an early stage in the transformation process...
  13. ncbi Tumor endothelial marker 8 enhances tumor immunity in conjunction with immnization against differentiation Ag
    P Felicetti
    Swim Across America Laboratory of Tumor Immunology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cytotherapy 9:23-34. 2007
    ..Tumor endothelial marker 8 (TEM8) is expressed in the neovasculature of human tumors, and in the mouse melanoma B16, but its expression is limited in normal adult tissues. We describe a DNA vaccine combining xenogeneic tumor Ag and TEM8...
  14. ncbi Insect cells as HLA-restricted antigen-presenting cells for the IFN-gamma elispot assay
    S Janetzki
    Swim Across America Laboratory and Departments of Surgery and Medicine, Memorial Sloan Kettering Cancer Center, New York 10021, USA
    J Immunol Methods 234:1-12. 2000
    ..Insect cells expressing human HLA molecules provide a standard APC for monitoring CD8(+) T cell responses to tumor and viral peptides during immunotherapy...
  15. pmc Induction of pigmentation in mouse fibroblasts by expression of human tyrosinase cDNA
    B Bouchard
    Memorial Sloan Kettering Cancer Center, New York 10021
    J Exp Med 169:2029-42. 1989
    ....
  16. ncbi In vitro expansion of Ag-specific T cells by HLA-A*0201-transfected K562 cells for immune monitoring
    J Yuan
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cytotherapy 8:498-508. 2006
    ..We have established a reproducible method using peptide-pulsed K562-A*0201 cells as APC to expand Ag-specific T cells in vitro. This method may be applied for monitoring T-cell responses in cancer immunotherapy clinical trials...
  17. ncbi Diverse roles of conserved asparagine-linked glycan sites on tyrosinase family glycoproteins
    Y Xu
    The Swim Across America Laboratory, The Weill Graduate School of Medical Sciences of Cornell University, New York, New York 10021, USA
    Exp Cell Res 267:115-25. 2001
    ..Different glycan sites on the same tyrosinase family polypeptide can perform distinct functions, and conserved sites on tyrosinase family paralogues can perform different functions...
  18. pmc Coupling and uncoupling of tumor immunity and autoimmunity
    W B Bowne
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Exp Med 190:1717-22. 1999
    ..e., antibody versus CD8(+) T cell. However, both pathways led to tumor immunity and identical phenotypic manifestations of autoimmunity...
  19. pmc A marker for neoplastic progression of human melanocytes is a cell surface ectopeptidase
    M E Morrison
    Memorial Sloan Kettering Cancer Center, New York, New York 10021
    J Exp Med 177:1135-43. 1993
    ..These findings show that ADAbp is a cell surface ectopeptidase that is tightly regulated during neoplastic transformation of melanocytes...
  20. ncbi Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center
    P J Bergman
    Donaldson Atwood Cancer Clinic and Flaherty Comparative Oncology Laboratory, The Animal Medical Center, 510 East 62nd Street, New York, NY 10021, USA
    Vaccine 24:4582-5. 2006
    ..These studies provided the impetus for development of a xenogeneic DNA vaccine program in CMM...
  21. pmc Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: a phase I trial
    T Gilewski
    Department of Medicine, Memorial Sloan-Kettering Cancer Center, Laboratories of Bio-Organic Chemistry, Sloan-Kettering Institute, 1275 York Avenue, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 98:3270-5. 2001
    ..Affinity column purification supported the specificity of IgM antibodies for globo H. On the basis of these data, globo H will constitute one component of a polyvalent vaccine for evaluation in high-risk breast cancer patients...
  22. ncbi Reactivity of autologous CD4+ T lymphocytes against human melanoma. Evidence for a shared melanoma antigen presented by HLA-DR15
    T Takahashi
    Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10021
    J Immunol 154:772-9. 1995
    ..Thus, by cytotoxicity assays, shared Ags were only recognized on melanoma cells but not on normal melanocytes. In summary, this analysis shows that melanoma cells share an Ag that is presented by HLA-DR15...
  23. pmc The melanoma antigen gp75 is the human homologue of the mouse b (brown) locus gene product
    S Vijayasaradhi
    Immunology Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021
    J Exp Med 171:1375-80. 1990
    ..The brown locus determines coat color in the mouse, suggesting that gp75 regulates or influences the type of melanin synthesized...
  24. ncbi Assignment of the human TYRP (brown) locus to chromosome region 9p23 by nonradioactive in situ hybridization
    V V Murty
    Memorial Sloan Kettering Cancer Center, New York, New York 10021
    Genomics 13:227-9. 1992
    ..The 9p region has been reported to be nonrandomly altered in human melanoma, suggesting a role for the region near the TYRP locus in melanocyte transformation...
  25. pmc Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma
    Jack C F Liao
    Flaherty Comparative Oncology Laboratory, Donaldson Atwood Cancer Clinic, The Animal Medical Center, New York, NY 10021, USA
    Cancer Immun 6:8. 2006
    ..Most interestingly, the onset of antibody induction in these three dogs coincides with observed clinical responses and may suggest a means to account for their long-term tumor control and survival...
  26. ncbi Langerhans-type dendritic cells genetically modified to express full-length antigen optimally stimulate CTLs in a CD4-dependent manner
    Jianda Yuan
    Laboratory of Cellular Immunobiology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Immunol 176:2357-65. 2006
    ..LCs, transduced with a retroviral vector encoding full-length Ag, stimulate potent CTLs directed against multiple epitopes in a CD4(+) Th cell-dependent manner...
  27. ncbi Autoimmunity and tumor immunity induced by immune responses to mutations in self
    Manuel E Engelhorn
    Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
    Nat Med 12:198-206. 2006
    ..Thus, presentation of a vast repertoire of antigen variants to the immune system can enhance the generation of adaptive immune responses to self...
  28. pmc Optimization of a self antigen for presentation of multiple epitopes in cancer immunity
    Jose A Guevara-Patino
    Swim Across America Laboratory of Tumor Immunology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Clin Invest 116:1382-90. 2006
    ....
  29. ncbi Estimates of stage-specific survival are altered by changes in the 2002 American Joint Committee on Cancer staging system for melanoma
    Leah Ben-Porat
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 106:163-71. 2006
    ....
  30. ncbi Comparison of two cancer vaccines targeting tyrosinase: plasmid DNA and recombinant alphavirus replicon particles
    Stacie M Goldberg
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 11:8114-21. 2005
    ..The purpose of this study was to compare viral and plasmid DNA in combination vaccination strategies in the context of a tumor antigen...
  31. pmc Antiviral T cell responses: phalanx or multipronged attack?
    David N Posnett
    Department of Medicine, Division of Hematology Oncology, Weill Medical College, Cornell University, New York, NY 10021, USA
    J Exp Med 201:1881-4. 2005
    ..Later, in the battle of Marathon described by Herodotus, the Greeks learned the advantages of multipronged attacks, a strategy still used in modern warfare. Is the immune system similar in its approach to combatting pathogens or tumors?..
  32. pmc Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity
    Adam D Cohen
    Swim Across America Laboratory of Tumor Immunology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Res 66:4904-12. 2006
    ..Finally, this effect on vaccine-induced CD8(+) T-cell responses was partially independent of CD4(+) T cells (both helper and regulatory), consistent with a direct costimulatory effect on the effector CD8(+) cells themselves...
  33. pmc A T-cell receptor associated with naturally occurring human tumor immunity
    Bianca D Santomasso
    Howard Hughes Medical Institute, Laboratory of Molecular Neuro Oncology, The Rockefeller University, New York, NY 10065, USA
    Proc Natl Acad Sci U S A 104:19073-8. 2007
    ..Cloned cdr2-specific TCR genes provide a clinically relevant means for immunologic targeting of human gynecologic cancers...
  34. ncbi Antibody and CD8+ T cell responses against HER2/neu required for tumor eradication after DNA immunization with a Flt-3 ligand fusion vaccine
    Francesca Orlandi
    Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 13:6195-203. 2007
    ..HER2/neu is frequently overexpressed in breast cancer. In a mouse model, vaccination with HER2/neu DNA elicits antibodies that confer partial protection against tumor challenge...
  35. ncbi Safety and immunogenicity of tyrosinase DNA vaccines in patients with melanoma
    Jedd D Wolchok
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Mol Ther 15:2044-50. 2007
    ..Mouse and human TYR DNA vaccines were found safe and induced CD8(+) T-cell responses in 7 of 18 patients. T cells recognizing a native TYR peptide had a phenotype consistent with that of effector memory cells...
  36. ncbi Stage-IV melanoma and pulmonary metastases: factors predictive of survival
    Heather B Neuman
    Gastric and Mixed Tumor Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Room H1221, New York, New York 10021, USA
    Ann Surg Oncol 14:2847-53. 2007
    ..We reviewed a contemporary, single-institution experience to evaluate the natural history of stage-IV melanoma metastatic to the lung and identify factors predictive of survival...
  37. ncbi Immunological validation of the EpitOptimizer program for streamlined design of heteroclitic epitopes
    Colin S B Houghton
    The Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10021, United States
    Vaccine 25:5330-42. 2007
    ..These data demonstrate that this approach can serve as the basis of epitope-engineering against cancer and intracellular pathogens...
  38. ncbi Immunization of high-risk breast cancer patients with clustered sTn-KLH conjugate plus the immunologic adjuvant QS-21
    Teresa A Gilewski
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 13:2977-85. 2007
    ..To determine the clinical toxicities and antibody response against sTn and tumor cells expressing sTn following immunization of high-risk breast cancer patients with clustered sTn-KLH [sTn(c)-KLH] conjugate plus QS-21...
  39. ncbi Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma
    Wen Jen Hwu
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 106:2445-51. 2006
    ..Therefore, the efficacy and safety of temozolomide in combination with pegylated IFN-alpha-2b in patients with metastatic melanoma without brain metastases was investigated...
  40. ncbi Adjuvanticity of plasmid DNA encoding cytokines fused to immunoglobulin Fc domains
    Cristina R Ferrone
    The Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, Weill Medical and Graduate Schools of Cornell University, New York, NY 10021, USA
    Clin Cancer Res 12:5511-9. 2006
    ..We compared DNA adjuvants for their ability to enhance immunity against a poorly immunogenic self-antigen expressed by cancer...
  41. ncbi Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102)
    Susan E Krown
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 107:1883-90. 2006
    ..To confirm these observations the combination was tested in a multicenter Phase II trial in patients with melanoma brain metastases...
  42. ncbi DNA immunization against tissue-restricted antigens enhances tumor immunity after allogeneic hemopoietic stem cell transplantation
    Miguel Angel Perales
    Swim Across America Laboratory of Tumor Immunology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Immunol 177:4159-67. 2006
    ..These results demonstrate that DNA immunization against tissue-restricted Ags after allogeneic T cell-depleted HSCT can induce potent antitumor effects without causing GVHD...
  43. ncbi Melanoma
    Alan N Houghton
    J Natl Compr Canc Netw 4:666-84. 2006
  44. ncbi Glucocorticoid-induced TNF receptor family related gene activation overcomes tolerance/ignorance to melanoma differentiation antigens and enhances antitumor immunity
    Teresa Ramirez-Montagut
    Department of Medicine and Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Immunol 176:6434-42. 2006
    ..Thus, we conclude that overall, GITR stimulation overcomes self-tolerance/ignorance and enhances T cell-mediated antitumor activity with minimal autoimmunity...
  45. doi Mechanisms of immunization against cancer using chimeric antigens
    Manuel E Engelhorn
    The Swim Across America Laboratory, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Mol Ther 16:773-81. 2008
    ..Therefore large fusion vector panels such as those presented here can provide information to promote the successful advancement of gene-based vaccines...
  46. ncbi Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study
    Wen Jen Hwu
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 103:2590-7. 2005
    ..The current Phase II study examined the efficacy and safety of this combination in chemotherapy-naive patients with brain metastases...
  47. ncbi Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunity
    Teresa Ramirez-Montagut
    Memorial Sloan Kettering Cancer Center and the Weill Graduate School of Medical Sciences of Cornell University, 1275 York Avenue, New York, NY 10021, USA
    Oncogene 22:3180-7. 2003
    ..Vitiligo (autoimmune hypopigmentation) can be mediated by T cells, FcgammaR+macrophages and/or complement...
  48. ncbi Induction of autoantibodies against tyrosinase-related proteins following DNA vaccination: unexpected reactivity to a protein paralogue
    Roopa Srinivasan
    Swim Across America Laboratory and Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Medical College and Graduate School of Cornell University, New York, NY 10021, USA
    Cancer Immun 2:8. 2002
    ..This represents an example of intermolecular determinant recognition, but is not simply due to epitope spreading since antibodies against the antigen targeted by DNA vaccination are not typically detected...
  49. ncbi A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen
    Jason S Gold
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Immunol 170:5188-94. 2003
    ....
  50. ncbi Classification of clear-cell sarcoma as a subtype of melanoma by genomic profiling
    Neil H Segal
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 21:1775-81. 2003
    ..CCS/MSP also has typical melanoma features, including immunoreactivity for S100 and HMB45, pigmentation, MITF-M expression, and a propensity for regional lymph node metastases...
  51. ncbi Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial
    Philip J Bergman
    Donaldson Atwood Cancer Clinic and Flaherty Comparative Oncology Laboratory, The E and M Bobst Hospital of the Animal Medical Center, New York, New York 10021, USA
    Clin Cancer Res 9:1284-90. 2003
    ..These studies provided the rationale for a trial of xenogeneic DNA vaccination in CMM using the human tyrosinase gene...
  52. ncbi The role of lipopolysaccharide in T-cell responses following DNA vaccination
    William G Hawkins
    Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Vaccine 21:1548-53. 2003
    ..CD8(+) T-cell responses were readily induced in TLR4-deficient mice immunized with DNA depleted of LPS. LPS in DNA vaccines is not required for CD8(+) T-cell responses...
  53. ncbi Multiple pathways to tumor immunity and concomitant autoimmunity
    Mary Jo Turk
    1Weill Graduate School of Medical Sciences of Cornell University, New York, USA
    Immunol Rev 188:122-35. 2002
    ..Autoimmunity uses similar mechanisms as tumor immunity, but tumor immunity and autoimmunity can uncouple. These studies open up strategies for active immunization against cancer...
  54. ncbi Redundant and alternative roles for activating Fc receptors and complement in an antibody-dependent model of autoimmune vitiligo
    Jiri Trcka
    The Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center and Weill Graduate School of Cornell University, New York, NY 10021, USA
    Immunity 16:861-8. 2002
    ..Thus, either complement or macrophages expressing activating Fc gamma R can independently and alternatively mediate disease in a model of autoimmune vitiligo...
  55. ncbi Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial
    Wen Jen Hwu
    Departments of Medicine, Epidemiology and Biostatistics, and Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 20:2610-5. 2002
    ..To establish a safe and tolerated regimen of an oral cytotoxic agent, temozolomide, and a cytostatic agent, thalidomide, in patients with unresectable stage III or IV malignant melanoma...
  56. ncbi T-cell responses against tyrosinase 368-376(370D) peptide in HLA*A0201+ melanoma patients: randomized trial comparing incomplete Freund's adjuvant, granulocyte macrophage colony-stimulating factor, and QS-21 as immunological adjuvants
    Susanne G Schaed
    Swim Across America Laboratory of Tumor Immunology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 8:967-72. 2002
    ....
  57. ncbi GM-CSF DNA induces specific patterns of cytokines and chemokines in the skin: implications for DNA vaccines
    Miguel Angel Perales
    The Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cytokines Cell Mol Ther 7:125-33. 2002
    ..These results have implications for understanding early events in the immune response to DNA vaccines, and provide a basis for development of new approaches to cancer vaccines, including the use of cytokine genes as adjuvants...
  58. ncbi Xenogeneic DNA immunization in melanoma models for minimal residual disease
    William G Hawkins
    Swim Across America Laboratory, Departments of Surgery and Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
    J Surg Res 102:137-43. 2002
    ....
  59. pmc Induction of autoantibodies to syngeneic prostate-specific membrane antigen by xenogeneic vaccination
    Polly D Gregor
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Cancer 116:415-21. 2005
    ..These results establish the basis for clinical trials to test PSMA DNA vaccines in patients with solid tumors that either express PSMA directly or that depend on normal endothelial cells expressing PSMA for their continued growth...
  60. ncbi CD8+ T-cell-dependent immunity following xenogeneic DNA immunization against CD20 in a tumor challenge model of B-cell lymphoma
    Maria Lia Palomba
    Department of Medicine and Immunology Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 11:370-9. 2005
    ..These results show that active immunization with xenogeneic DNA vaccines can induce CD8+ T cell-dependent immunity against CD20...
  61. pmc Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells
    Mary Jo Turk
    The Swim Across America Laboratory of Tumor Immunology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Exp Med 200:771-82. 2004
    ..These results show that regulatory T cells are the major regulators of concomitant tumor immunity against this weakly immunogenic tumor...
  62. pmc GITR activation induces an opposite effect on alloreactive CD4(+) and CD8(+) T cells in graft-versus-host disease
    Stephanie J Muriglan
    Department of Medicine and Immunology, Memorial Sloan Kettering Cancer Center, Kettering 425, Mailbox 111, 1275 York Ave, New York, NY 10021, USA
    J Exp Med 200:149-57. 2004
    ..Our findings indicate that GITR has opposite effects on the regulation of alloreactive CD4(+) and CD8(+) T cells...
  63. ncbi FAPalpha, a surface peptidase expressed during wound healing, is a tumor suppressor
    Teresa Ramirez-Montagut
    Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center and Weill Graduate School of Medical Sciences of Cornell University, 1275 York Avenue, New York, NY 10021, USA
    Oncogene 23:5435-46. 2004
    ..These results show that expression of FAP is a tumor suppressor that abrogates tumorigenicity through regulation of cell growth and survival...
  64. ncbi CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems
    Polly D Gregor
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Vaccine 22:1700-8. 2004
    ..Based on these pre-clinical studies, we suggest that anti-CTLA-4 should be tested with xenogeneic DNA vaccines against cancer and that special attention should be given to sequence and schedule of administration...
  65. ncbi Role for dipeptidyl peptidase IV in tumor suppression of human non small cell lung carcinoma cells
    Umadevi V Wesley
    Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Int J Cancer 109:855-66. 2004
    ..Thus, DPPIV functions as a tumor suppressor, and its downregulation may contribute to the loss of growth control in NSCLC cells...
  66. ncbi Immunity to cancer through immune recognition of altered self: studies with melanoma
    Jose A Guevara-Patino
    Memorial Sloan Kettering Cancer Center and the Weill Graduate School of Medical Sciences and Medical School of Cornell University, 1275 York Avenue, New York, NY 10021, USA
    Adv Cancer Res 90:157-77. 2003
    ..Studies examining the molecular basis for immunogenicity of conserved paralogues are facilitating the development of new strategies to rationally design vaccines that trigger adaptive immune responses to cancer...
  67. ncbi Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma
    Wen Jen Hwu
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 21:3351-6. 2003
    ..To further investigate the efficacy and safety of temozolomide plus thalidomide in patients with metastatic melanoma without brain metastases...
  68. pmc Classification and subtype prediction of adult soft tissue sarcoma by functional genomics
    Neil H Segal
    Swim Across America Laboratory, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York and Columbia Genome Center, Columbia University, New York, New York 10021, USA
    Am J Pathol 163:691-700. 2003
    ..In conclusion, we showed gene expression profiling to be useful in classification and diagnosis, providing insights into pathogenesis and pointing to potential new therapeutic targets of soft tissue sarcoma...
  69. ncbi Strategies to overcome immune ignorance and tolerance
    Miguel Angel Perales
    Memorial Sloan Kettering Cancer Center and Weill Medical School and Graduate School of Cornell University, New York, NY 10021, USA
    Semin Cancer Biol 12:63-71. 2002
    ..Crucial to these approaches is the discovery and understanding of the molecular identity of antigens and the mechanisms involved in tumor immunity. In this review, strategies to overcome immune ignorance and tolerance are discussed...
  70. ncbi Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues
    Alexis Gorden
    Ronald O Perelman Department of Dermatology, New York University School of Medicine, New York, New York 10016, USA
    Cancer Res 63:3955-7. 2003
    ..Our data show that BRAF mutation is common in melanoma metastases, regardless of their site, that mutations include both exons 11 and 15, and suggest that anti-RAS/RAF strategies may be effective in metastatic melanoma patients...

Research Grants19

  1. IMMUNIZATION AGAINST MELANOMA DIFFERENTIATION ANTIGENS
    Jedd D Wolchok; Fiscal Year: 2010
    ..The overall goal of this grant is to develop more effective strategies to use the immune system to recognize specific targets present on melanoma cells. ..
  2. IMMUNIZATION AGAINST MELANOMA DIFFERENTIATION ANTIGENS
    Alan Houghton; Fiscal Year: 2009
    ..In aim 4, we will continue to create more relevant mouse models of melanoma that develop endogenous invasive melanomas to study tumor immunity against differentiation and mutant antigens. ..
  3. Targeted antigen receptor treatment of cancer
    Alan Houghton; Fiscal Year: 2007
    ....
  4. IMMUNIZATION AGAINST MELANOMA DIFFERENTIATION ANTIGENS
    Alan Houghton; Fiscal Year: 2004
    ..and 3) Develop mouse models that develop endogenous invasive melanomas and study immunity against differentiation antigens at different steps in tumor progression. ..
  5. ACTIVE IMMUNOTHERAPY OF MELANOMA
    Alan Houghton; Fiscal Year: 1993
    ..These studies will give insights into immune recognition of differentiation and tumor-specific antigens expressed by cancer cells and provide strategies for construction of cancer vaccines...
  6. IMMUNIZATION AGAINST MELANOMA DIFFERENTIATION ANTIGENS
    ALAN N contact HOUGHTON; Fiscal Year: 2011
    ..The overall goal of this grant is to develop more effective strategies to use the immune system to recognize specific targets present on melanoma cells. ..